Altered hepatic metabolism of fatty acids in rats fed a hypolipidaemic drug, fenofibrate

Pharmacological Research

Volumn 33, Issue 6, 1996, Pages 337-342

  Yamamoto, Kyosuke ^a   Fukuda, Nobuhiro ^b   Zhang, Lei ^b   Sakai, Takahiro ^a  

^a SAGA UNIVERSITY   (Japan)

^b UNIVERSITY OF MIYAZAKI   (Japan)

Author keywords

Fatty acid oxidation; Fenofibrate; Perfused rat liver; Triglyceride secretion

Indexed keywords

3 HYDROXYBUTYRIC ACID; ACETOACETIC ACID; ANTILIPEMIC AGENT; FENOFIBRATE; KETONE BODY; OLEIC ACID;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; FATTY ACID METABOLISM; KETOGENESIS; LIVER METABOLISM; LIVER MITOCHONDRION; LIVER WEIGHT; MALE; NONHUMAN; OXIDATION REDUCTION POTENTIAL; PRIORITY JOURNAL; RAT;

EID: 0030175193     PISSN: 10436618     EISSN: None     Source Type: Journal    
DOI: 10.1006/phrs.1996.0046     Document Type: Article

References (37)

1. 1. Sirtori CR, Manzoni C, Lovati. Mechanisms of lipid-lowering agents. Cardiology 1991; 78: 226-35.
2. 2. Kritchevsky D, Tepper SA, Story JA. Influence of procetofen on lipid metabolism in normocholesterolemic rats. Pharmacol Res Commun 1979; 11: 635-41.
3. 3. Blane GF. Comparative toxicity and safety profile of fenofibrate and other fibric acid derivatives. Am J Med 1987; 83 (Suppl 5B): 26-36.
4. 4. Hunninghake DB, Peters JR. Effect of fibric acid derivatives on blood lipid and lipoprotein levels. Am J Med 1987; 83 (Suppl 5B): 44-9.
5. 5. Balfour JA, McTavish DM, Heel RC. Fenofibrate. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in dyslipidaemia. Drugs 1990; 40: 260-90.
6. 6. Tsuchiya A, Kasai H, Nagayama T, Saito K. Comparison of hypolipidemic action of fenofibrate, bezafibrate, clinofibrate and clofibrate in rats. Jpn Pharmacol Ther (Suppl) 1995; 23: 175-81.
7. 7. Caldwell J. The biochemical pharmacology of fenofibrate. Cardiology 1989; 76 (Suppl 1): 33-44.
8. 8. Kloer HU. Structure and biochemical effects of fenofibrate. Am J Med 1987; 83 (Suppl 5B): 3-8.
9. 9. Petit D, Bonnefis MT, Rey C, Infante R. Effects of ciprofibrate and fenofibrate on liver lipids and lipoprotein synthesis in normo-and hyperlipidemic rats. Atheroscler 1988; 74: 215-25.
10. 10. Heller F, Harvengt C. Effects of clofibrate, bezafibrate, fenofibrate and probucol on plasma lipolytic enzymes in normolipaemic subjects. Eur J Clin Pharmacol 1983; 25: 57-63.
11. 11. Weisweiler P. Low-dose of colestipol plus fenofibrate: effects on plasma lipoproteins, lecithin:cholesterol ayltransferase, and postheparin lipases in familial hypercholesterolemia. Metabol 1989; 38: 271-5.
12. 12. Foger B, Drexel H, Hopferwieser T, Miesenbock G, Ritsch A, Leichleitner M, Trobinger G. Fenofibrate improves postprandial chylomicron clearance in II B hyperlipoproteinemia. Clin Invest 1994; 72: 294-301.
13. 13. Cavellero E, Piolot A, Jacotot B. Postprandial lipoprotein clearance in type 2 diabetes: Fenofibrate effects. Diab Metabol 1995; 21: 118-20.
14. 14. Lazarow PB. Rat liver peroxisomes catalyze the β-oxidation of fatty acids. J Biol Chem 1978; 253: 1522-8.
15. 15. Mannaerts GP, Debeer LJ, Thomas J, De Schepper PJ. Mitochondrial and peroxisomal fatty acid oxidation in liver homogenates and isolated hepatocytes from control and clofibrate-treated rats. J Biol Chem 1979; 254: 4585-95.
16. 16. Stegmeir K, Schmidt FH, Reinicke A, Fahimi HD. Triglyceride lowering effect and induction of liver enzymes in male rats after administration of hypolipidemic drugs. Ann N Y Acad Sci 1982; 386: 449-52.
17. 17. Ide T, Oku H, Sugano M. Reciprocal responses to clofibrate in ketogenesis and triglyceride and cholesterol secretion in isolated rat liver. Metabol 1982; 31: 1065-72.
18. 18. Kusama H, Nishiyama M, Ikeda S. Pharmacological investigation of bezafibrate, a hypolipidemic agent (1). Effects of bezafibrate on normal and experimental hyperlipidemia in rats. Folia Pharmacol Jpn 1988; 92: 175-80.
19. 19. Kusama H, Nishiyama M, Matsubara Y, Ikeda S. Pharmacological investigation of ezafibrate, a hypolipidemic agent (2). Mechanism of the hypolipidemic action of bezafibrate in rats. Folia Pharmacol Jpn 1988; 92: 181-91.
20. 20. Barnard SD, Molello JA, Caldwell WJ, LeBeau JE. Comparative ultrastructural study of rat hepatocytes after treatment with the hypolipidaemic agents probucol, clofibrate, and fenofibrate. J Toxicol Environ Health 1980; 6: 547-57.
21. 21. Pourbaix S, Heller F, Harvengt C. Effect of fenofibrate and LF 2151 on hepatic peroxisomes in hamsters. Biochem Pharmacol 1984; 33: 3661-6.
22. 22. Veldhoven VP, Declercq PE, Debeer LJ, Mannaerts GP. Effects of benfluorex and fenofibrate treatment on mitochondrial and peroxisomal marker enzymes in rat liver. Biochem Pharmacol 1984; 33: 1153-5.
23. 23. Nagayama T, Tsuchiya A, Kasai H, Arakawa R, Saito K. Hypolipidemic mechanisms of fenofibrate (2): Lipid influx into the circulation of rats. Jpn Pharmacol Ther (Suppl 1) 1995; 23: 197-204.
24. 24. Fukuda N, Ontko JA. Interactions between fatty acid synthesis, oxidation, and esterification in the production of triglyceride-rich lipoproteins by the liver. J Lipid Res 1984; 25: 831-42.
25. 25. Fukuda N, Etoh T, Wada K, Hidaka T, Yamamoto K, Ikeda I, Sugano M. Differential effects of geometrical isomers of octadecadienoic acids on ketogenesis and lipid secretion in the livers from rats fed a cholesterol-enriched diet. Ann Nutr Metabol 1995; 39: 185-92.
26. 26. Fukuda N, Azain MJ, Ontko JA. Altered hepatic metabolism of free fatty acids underlying hypersecretion of very low density lipoproteins in the genetically obese Zucker rat. J Biol Chem 1982; 25: 14066-72.
27. 27. Folch J, Lees M, Sloane-Stanley GH. A simple method for the isolation and purification of total lipids from animal tissues. J Biol Chem 1957; 226: 497-509.
28. 28. Duncan DB. Multiple range and multiple F tests. Biometrics 1955; 11: 1-42.
29. 29. Hahn SE, Goldberg DM. Modulation of lipoprotein production in Hep G2 cells by fenofibrate and clofibrate. Biochem Pharmacol 1992; 43: 625-33.
30. 30. Yamamoto K, Fukuda N, Fukui M, Kai Y, Ikeda S, Sakai T. Increased secretion of triglyceride and cholesterol following inhibition of long-chain fatty acid oxidation in rat liver. Ann Nutr Metabol 1996; in press.
31. 31. Yamamoto M, Fukuda N, Triscari J, Sullivan AC, Ontko JA. Decreased hepatic production of very low density lipoproteins following activation of fatty acid oxidation by Ro 22-0654. J Lipid Res 1985; 26: 1196-204.
32. 32. Osmundsen H, Bremer J, Pedersen JI. Metabolic aspects of peroxisomal β-oxidation. Biochim Biophys Acta 1991; 1085: 141-58.
33. 33. Reddy JK, Mannaerts GP. Peroxisomal lipid metabolism. Annu Rev Nutr 1994; 14: 343-70.
34. 34. Laker ME, Mayes PA. The immediate and long term effects of clofibrate on the metabolism of the perfused rat liver. Biochem Pharmacol 1979; 28: 2813-27.
35. 35. Olivier P, Plancke MO, Theret N, Marzin D, Clavey V, Fruchart JC. Effects of fenofibrate on lipoprotein metabolism and fatty acid distribution in Zucker rats. Atheroscler 1988; 74: 15-21.
36. 36. Vessby B, Lithell H. Interruption of long-term lipid-lowering treatment with bezafibrate in hypertriglyceridaemic patients. Effects on lipoprotein composition, lipase activities and the plasma lipid fatty acid spectrum. Atheroscler 1990; 82: 137-43.
37. 37. Pascal M, Danh HC, Legendre C. Mechanisms of action of fenofibrate: New data. In: Paoletti R, Kritchevsky D, Holmeswl, eds. Drug affecting lipid metabolism. Berlin: Springer, 1987, p. 319-23.